EHA 2025 Highlights Podcast

In this episode, Medicom’s correspondent covers 6 presentations from the annual meeting of the European Hematology Association (EHA 2025), held in Milan, Italy, from 12-15 June 2025.

The topics discussed are:

1. inMIND: Positive phase 3 results for tafasitamab combination in FL

 The combination of tafasitamab, lenalidomide, and rituximab yielded clinically relevant benefits in survival outcomes in patients with relapsed or refractory follicular lymphoma (FL). Together with an acceptable safety profile, this regimen may potentially represent a new standard-of-care option for this indication.

2. Novel investigational gene-editing therapy for TDT and SCD

The investigational agent BRL-101 was associated with a manageable safety profile, durable efficacy, and improvements in quality-of-life in patients with either transfusion-dependent thalassaemia (TDT) or sickle cell disease (SCD).

3. Encouraging results for new mutation-specific targeted therapy in CALR-mutated ET

The experimental agent INCA33989 delivered swift and sustained haematologic responses in patients with essential thrombocythemia (ET). This mutation-specific targeted therapy was not associated with dose-limiting toxicities, supporting further investigation in a clinical trial programme.

4. MANIFEST-2: Sustained benefits of pelabresib plus ruxolitinib in myelofibrosis

The combination of pelabresib and ruxolitinib displayed improvements across a variety of efficacy measures in patients with JAK inhibitor-naïve myelofibrosis. Moreover, the 72-week follow-up data of the MANIFEST-2 trial showed that the addition of pelabresib to the treatment regimen was not associated with considerable toxicity in this population.

5. TUSCANY: Promising data for addition of tuspetinib in untreated chemo-ineligible AML

Preliminary data of the TUSCANY study indicated that tuspetinib can be added to standard-of-care venetoclax plus azacitidine in patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy, without adding safety issues to the treatment regimen. So far, the researchers observed promising anti-tumour activity across a diverse patient population, including patients with TP53 mutations.

6. Prognostic impact of circulating tumour cells in AL amyloidosis

Circulating tumour cells (CTCs) are less plentiful in patients with newly diagnosed light chain (AL) amyloidosis than in patients with multiple myeloma (MM). Therefore, more sensitive instruments are needed to detect these cells in AL amyloidosis. This is important, since CTCs seem to have a prognostic impact on survival outcomes.

 

Enjoy listening!

Copyright ©2025 Medicom Medical Publishers



Posted on 1 July 20252 July 2025